News & Views

  • Financing to Progress Lead Therapeutic to Clinic
    Dr Natalie Mount

Financing to Progress Lead Therapeutic to Clinic

May 06 2021

Following progress made by the company over the past 18 months, Adaptate Biotherapeutics (Adaptate), a developer of antibody-based therapeutics for modulation of gamma delta T cells, announced that its existing investors, Abingworth and Takeda Pharmaceutical Company Limited (Takeda), have together made a further equity investment of $18 million (circa. £13 million).  This funding brings the total raised since Adaptate’s inception in late 2019 to $34 million (circa. £25 million).

The funds will be used to accelerate the company’s lead therapeutic antibody programme towards the clinic and to expand its internal product pipeline through expanded R&D activities. This will encompass planned expansion in recruitment, laboratory and office space. The Company’s most advanced programmes are focussed on treatments for cancer patients with solid tumours.

Dr Natalie Mount, CEO of Adaptate Biotherapeutics, said: “The funding is a great vote of confidence from our existing investors and testimony to the hard work and rapid progress we have made in the novel field of gamma delta T cell targeting antibodies. We are excited to continue this growth path and to progress our unique therapeutic antibodies towards clinical trials where we look forward to them making an impact on the treatments available to cancer patients.”

More information online

Digital Edition

International Labmate Buyers' Guide 2021

June 2021

In This Edition Articles - NMR for Electrolyte Design - Specialty Chromatography Detectors: Make or Buy? - Energy Efficient Autoclaves - Misconceptions and Misunderstanding Mass Spectrom...

View all digital editions



Jun 21 2021 Dubai, UAE & Online

Arab Health - NEW DATES

Jun 21 2021 Dubai, UAE & Online


Jun 29 2021 Ljubljana, Slovenia

MMC 2021

Jul 05 2021 Online event

M&M 2021

Aug 01 2021 Virtual event

View all events